FCMI
VRNA

Foresite Capital Management IV’s Verona Pharma VRNA Stock Holding History

Foresite Capital Management IV’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,302
Closed -$104K – 23
2018
Q3 		$104K Buy
+8,302
New +$107K 0.03% 21

Other funds holding VRNA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Foresite Capital Management IV's VRNA Position: Q4 2018 in Review

Foresite Capital Management IV sold out of Verona Pharma (VRNA) in Q4 2018, closing a stake of 8,302 shares — an estimated $104K sold.

Foresite Capital Management IV first reported a position in VRNA in Q3 2018 and held it in 1 quarter. The position peaked at $104K in Q3 2018. 17 funds tracked by Wall St. Rank hold VRNA as of Q4 2018.

  • Foresite Capital Management IV reported no remaining Verona Pharma position as of Q4 2018 after selling out during the quarter.
  • Foresite Capital Management IV sold 8,302 Verona Pharma shares in Q4 2018, an estimated $104K.
  • Foresite Capital Management IV first reported a position in Verona Pharma in Q3 2018 and held it in 1 quarter.
  • Foresite Capital Management IV's Verona Pharma position peaked at $104K in Q3 2018.
  • 17 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2018.

Based on Foresite Capital Management IV's 13F filing for Q4 2018, filed 13 Feb 2019.